Comparative efficacy and safety of daclatasvir/asunaprevir versus IFN-based regimens in genotype 1b hepatitis C virus infection

Signorovitch, James; Betts, Keith A.; Song, Yan; Sorg, Rachael; Li, Junlong; Behl, Ajay S.; Kalsekar, Anupama

doi:10.2217/cer.15.33

Cited by 5 publications

(4 citation statements)

References 48 publications

(70 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…DCV plus ASV was well tolerated in both studies with few AEs leading to treatment discontinuation. Consistent with phase 3 results, a network meta‐analysis found that this combination was more effective and better tolerated than pegIFN/RBV alone or combined with telaprevir, boceprevir or simeprevir .…”

mentioning

confidence: 56%

Daclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysis

Kao

Manns

Jacobson

et al. 2016

Liver International

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 56%

Daclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysis

Kao

Manns

Jacobson

et al. 2016

Liver International

View full text Add to dashboard Cite

show abstract

“…Because no "head-to-head" studies comparing DCV/ASV versus PR and PIs/PR is available, data from a network meta-analysis (NMA) was used [ 19 ]. The main objective of this study was to compare the results of efficacy and tolerability of DCV/ASV, PR, PIs/PR among other alternatives, in different groups of patients.…”

Section: Methodsmentioning

confidence: 99%

Cost Effectiveness of Daclatasvir/Asunaprevir Versus Peginterferon/Ribavirin and Protease Inhibitors for the Treatment of Hepatitis c Genotype 1b Naïve Patients in Chile

et al. 2015

View full text Add to dashboard Cite

IntroductionDaclatasvir and Asunaprevir (DCV/ASV) have recently been approved for the treatment of chronic hepatitis C virus infection. In association, they are more effective and safer than previous available treatments, but more expensive. It is unclear if paying for the additional costs is an efficient strategy considering limited resources.MethodsA Markov model was built to estimate the expected costs in Chilean pesos (CL$) and converted to US dollars (US$) and benefits in quality adjusted life years (QALYs) in a hypothetic cohort of naive patients receiving DCV/ASV compared to protease inhibitors (PIs) and Peginterferon plus Ribavirin (PR). Efficacy was obtained from a mixed-treatment comparison study and costs were estimated from local sources. Utilities were obtained applying the EQ-5D survey to local patients and then valued with the Chilean tariff. A time horizon of 46 years and a discount rate of 3% for costs and outcomes was considered. The ICERs were estimated for a range of DCV/ASV prices. Deterministic and probabilistic sensitivity analyses were performed.ResultsPIs were extendedly dominated by DCV/ASV. The ICER of DCV/ASV compared to PR was US$ 16,635/QALY at a total treatment price of US$ 77,419; US$11,581 /QALY at a price of US$ 58,065; US$ 6,375/QALY at a price of US$ 38,710; and US$ 1,364 /QALY at a price of US$ 19,355. The probability of cost-effectiveness at a price of US$ 38,710 was 91.6% while there is a 21.43% probability that DCV/ASV dominates PR if the total treatment price was US$ 19,355. Although the results are sensitive to certain parameters, the ICER did not increase above the suggested threshold of 1 GDP per capita.ConclusionsDCV/ASV can be considered cost-effective at any price of the range studied. These results provide decision makers useful information about the value of incorporating these drugs into the public Chilean healthcare system.

show abstract

“…The review of published literature revealed a study of indirect comparisons of effectiveness of regimens DCV + ASV, SMV + PegIFN +RBV and PegIFN + RBV, which used two methods CSL [7]:…”

Section: Analysis Of Efficacy: DCV + Asv Smv + Pegifn +Rbv and Pegifmentioning

confidence: 99%

Pharmacoeconomic analysis of combination of medicines daclatasvir and asunaprevir in treatment of chronic hepatitis C in the Russian Federation

Kulikov¹,

Babiy²,

Shestakova³

2016

Pharmacoeconom T&P

View full text Add to dashboard Cite

The goals of this study was: 1. to evaluate the superior regimen of antiviral drug treatment of chronic hepatitis C (daclatasvir + asunaprevir (a combination of the medicinal products) versus perginterferon alfa + ribavirin or peginterferon alfa + ribavirin + simeprevir or paritaprevir + ritonavir + ombitasvir + dasabuvir) in treatment-naive and treatment-experienced patients (HCV genotype 1b) without liver cirrhosis and with liver cirrhosis based on comparison of cost, effectiveness and safety; 2. To define, using «budget impact» analysis, economic outcomes of including daclatasvir + asunaprevir in current practice of HCV treatment This analysis was performed using two scenarios of the adjusted model "The MONARCH Cost-effectiveness Model". «Budget impact» analysis was conducted using adapted model «ALLY: Daklinza ® (Daclatasvir) Budget Impact Model». The study demonstrated that the first study hypothesis was correct: the combination of the medicinal products for treatment of HCV-infection (HCV genotype 1) daclatasvir + asunaprevir was found to have advantages over the combinations peginterferon alfa + ribavirin, peginterferon alfa + ribavirin + simeprevir and dasabuvir, ombitasvir + paritaprevir + ritonavir in respect of the cost-effectiveness ratio. Furthermore, results of «budget impact» analysis confirmed the second study hypothesis-introduction of DCV + ASV in current practice of HCV treatment will lead to decreasing of complication treatment costs.

show abstract

Comparative efficacy and safety of daclatasvir/asunaprevir versus IFN-based regimens in genotype 1b hepatitis C virus infection

Abstract: DCV + ASV demonstrated superior efficacy and safety compared with A/R-based regimens.

Cited by 5 publications

References 48 publications

Daclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysis

Daclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysis

Cost Effectiveness of Daclatasvir/Asunaprevir Versus Peginterferon/Ribavirin and Protease Inhibitors for the Treatment of Hepatitis c Genotype 1b Naïve Patients in Chile

Pharmacoeconomic analysis of combination of medicines daclatasvir and asunaprevir in treatment of chronic hepatitis C in the Russian Federation

Contact Info

Product

Resources

About